Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study

Data from a multicenter retrospective analysis of patients with relapsed/refractory DLBCL who received CAR T-cell therapy (with axicabtagene ciloleucel or tisagenlecleucel) demonstrated comparable outcomes between those age <70 versus age ≥70 years. With a median follow-up of 8.3 months, median PFS was 10.2 months (95% CI: 6.5–21.8) vs 11.1 months (95% CI: 4.9–NR; p = 0.93), respectively, and median OS was 21.8 months (95% CI: 11.8–NR) vs 34.4 months (95% CI: 10.1–NR; p = 0.97), respectively. No significant differences in the incidence of cytokine release syndrome or grade ≥3 neurotoxicity were observed.